Results 11 to 20 of about 50,442 (246)
Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL
Frontiers in ImmunologyIntroductionChimeric antigen receptor (CAR) T-cell therapies have achieved remarkable success in treating B-cell malignancies, including acute lymphoblastic leukemia (B-ALL).
Jennifer Bolsée +5 more
doaj +2 more sources
CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity [PDF]
Cancers, 2021 CAR-T cell therapy is not without some clinical adverse effects, namely cytokine storms, due to a massive release of cytokines when CAR-T cells multiply in the body. Our goal was to develop exosomes expressing CD19 CAR to treat CD19-positive B-cell malignancies, instead of using whole CD19 CAR-T cells, thereby reducing the clinical risk of uncontrolled
Shabirul Haque, Sarah R. Vaiselbuh
openaire +2 more sources
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19 [PDF]
Nature Communications, 2022 AbstractWhile chimeric antigen receptor (CAR) T cells targeting CD19 can cure a subset of patients with B cell malignancies, most patients treated will not achieve durable remission. Identification of the mechanisms leading to failure is essential to broadening the efficacy of this promising platform.
Amanda Heard +18 more
openaire +4 more sources
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors [PDF]
Journal of Translational Medicine, 2013 Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain capable of activating T-cells. CARs displayed on the surface of transduced cells perform non-MHC-restricted antigen recognition and activating intracellular signaling pathways for induction of target cytolysis,
De Oliveira, SN +5 more
openaire +6 more sources
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies [PDF]
Journal of Clinical Investigation, 2016 Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients ...
Marco Ruella +20 more
openaire +2 more sources
International Journal of Nanomedicine, 2023 CAR-T cell therapy is effective in the treatment of certain hematological malignancies, and the expansion and functional persistence of CAR-T cells in vivo are crucial to clinical efficacy. The aim of this study was to investigate the potential of extracellular vesicles (EVs) modified with the CAR antigen to promote the efficacy of CAR-T cells in vivo ...
Yuanyuan Zhang +10 more
openaire +4 more sources
Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis
Cureus, 2022 The purpose of this case report was to present a case of cytomegalovirus (CMV) retinitis in a patient with diffuse large B-cell lymphoma (DLBCL) post-CD19 chimeric antigen receptor (CAR) T-cell therapy. A 43-year-old female patient who was complaining of metamorphopsia and sudden blurring in the vision of her left eye was referred to the ophthalmology ...
Bin dokhi, Haifa +4 more
openaire +2 more sources
Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
Leukemia Research Reports, 2018 Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent ...
Gina Ma +7 more
openaire +3 more sources
BLDE University Journal of Health Sciences, 2022 BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease as it affects multiple lineages of hematopoietic cells. AIMS AND OBJECTIVES: This study aims to (1) evaluate the immunophenotypic findings of AML patients, (2) correlate the ...
Mekhala Rao +3 more
doaj +1 more source
Hematology/Oncology and Stem Cell Therapy, 2013 BACKGROUND AND OBJECTIVES: The role of bone marrow-mesenchymal stem cells (BM-MSC) in leukae-mic cell control is controversial. The purpose of this work was to evaluate BM-MSC role regarding the viability, proliferation and immunophenotype of normal B ...
Viviana M Rodríguez-Pardo +7 more
doaj +1 more source